$CLBT

Barter David (Chief Financial Officer) sold 12,134 shares of Cellebrite DI Ltd. (CLBT) at $11.21 ($0.14M total) on 2026-10-16.

Pertento Partners LLP, Pertento Advisors LLC, and Eduardo Marques each reported a 5.2% passive stake in Cellebrite DI Ltd. (CLBT), owning 13,164,696 shares with shared voting and dispositive power. The shares are directly owned by advisory clients, with no beneficial ownership claimed beyond pecuniary interest.

Cellebrite DI Ltd. shareholders approved CEO Shiven Ramji's pay package, re-elected directors, and re-appointed auditors at their annual meeting on September 24, 2026. 80.9% of shares were represented, per the company's SEC filing.

Cellebrite DI Ltd (NASDAQ: CLBT) plans a corporate reorganization under a new U.S.-based parent company, pending approvals, to streamline operations and unlock shareholder value. GF Value™ estimates CLBT is 31.7% undervalued at $11.23 vs. an intrinsic value of $16.44. The company has a GF Score™ of 81/100, indicating strong fundamentals, but insiders have sold $5.2 million in shares over the past year.

Cellebrite DI Ltd. (CLBT) named CTO Chris Wade to lead Cellebrite Labs, focusing on mobile access, extraction, and decoding research. The move follows the Corellium acquisition, aiming to streamline R&D efforts.

Cellebrite (CLBT) plans to redomicile in the U.S. by mid-2027, pending approvals. The move aims to boost growth in key markets and attract more investors. CEO Shiv Ramji cited strategic benefits, including inclusion in key indices. Details will be shared in SEC filings.

Cellebrite DI (CLBT) announced its Guardian cloud platform received a PROTECTED-level IRAP assessment for Australian public sector use, and launched the C TEK backpack kit for military forensics. These developments could impact contract structures, deployment costs, and long-term demand from government clients. The company projects $787.4M revenue and $122.0M earnings by 2029, implying 15.3% yearly revenue growth. Analysts' fair value estimates range from $12.50 to $15.36, with the current share

Cellebrite DI (CLBT) has seen its stock decline 28.48% in the past month and 35.82% year-to-date, despite a 3-year return of 45.30%. The company recently announced two product updates: Guardian platform cleared an Australian IRAP PROTECTED assessment, and the new C TEK field kit expands its defense offerings. Analysts debate its valuation, with a fair value estimate of $15.36 compared to its last close at $11.45, while its P/E ratio of 49.3x raises concerns about potential overvaluation.

Cellebrite DI Ltd. (CLBT) announced that its cloud-based digital evidence management platform, Guardian, has achieved a PROTECTED classification level under the Infosec Registered Assessors Program (IRAP) in Australia. This milestone allows Australian government agencies to use Guardian for secure digital evidence collaboration. The assessment was conducted by CyberCX, an Australian Signals Directorate-endorsed IRAP assessor.

Cellebrite DI Ltd (CLBT) announced its subsidiary achieved CMMC Level 2 certification. GF Value™ estimates CLBT is 26.6% undervalued at $12.01 vs. $16.36 intrinsic value. CLBT has a GF Score™ of 87, strong financials, and 11.2% 3-year revenue growth. Insiders sold $5.2M shares, while 5 gurus hold positions.